Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 2.48% 8.25 8.00 8.50 8.35 8.05 8.05 180,004 13:49:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.1 -2.7 - 11

Evgen Pharma Share Discussion Threads

Showing 1826 to 1850 of 1850 messages
Chat Pages: 74  73  72  71  70  69  68  67  66  65  64  63  Older
DateSubjectAuthorDiscuss
14/11/2019
15:21
This should return to 10p+ in the near future, looking forward to seeing how the board reacts too.
90005nelson
14/11/2019
12:22
The Newlands have taken the opportunity to increase their holding by 1.5% to 6.19% of EVG!
dave444
14/11/2019
09:38
It looks like 5.5 on 11th should turn out to be a decent low. 231 days from the 28.55 top and 23 p down from there.
langland
13/11/2019
21:31
Oh dear another moron turns up!He hasn't done any facts and analysis - I even had to point him to a specific piece of information which he continued to ignore the clear information and make up spurious claims!It has already proven efficacy and safety in breast cancer!!!!!Furthermore it has patented the solution so no competitors can arise!!On top of that they clearly state looking for a partner who will donate a hefty up front fee plus royalties
dave444
13/11/2019
21:23
Yeah! Take your facts and your analysis and go somewhere else. I’m much happier with a combination of wishful thinking, fingers in my ears and buyers remorse thank you very much.
ardinno
13/11/2019
19:06
Go buy some other share
dave444
13/11/2019
17:46
so that would be $100mill a year in about 7 years for evg. Market cap would be about $1billion-$2billion, 100/200 times it's current value. £7/£14 per share. What's the chance of Phase IIb and Phase III being positive? That's incredibly difficult to predict. 5% of cancer drugs that enter phase I trials ultimately gain FDA approval, so could guess at 5% chance of regulatory approval. It's a very crude estimate though because it doesn't include any weighting for potential competitor drugs, low powered study of small companies like EVG, and the fact that it has already made it to phase II. A 1 in 20 bet for a 100/1 payout in 7 years. That's assuming all other indications have zero value because they are such early stage.
asat91
13/11/2019
17:18
I think in their communications they were talking of double digit royalty percentages
dave444
13/11/2019
17:00
Let's assume $1billion/year for SFX-01 happens at some point in the future. How long do you think it will be until that happens? What percentage of that money do you think EVG will see?
asat91
13/11/2019
15:33
Market opportunity for SFX-01 is initially second-line therapy post-CDK4/6i failure Everolimus + Exemestane Fulvestrant SFX-01 + Fulvestrant Safety profile Poor Good Good (Target) Efficacy (Progression-Free Survival) 7.8 months 3 to 6 months > or = 7.8 months (Target) Sales Everolimus $1.5bn1 Fulvestrant $940m2 SFX-01 >$1bn3  Substantial market opportunity – CDK4/6i sales projected to reach c.$9bn by 2021e4  Partner SFX-01 as second-line therapy to CDK4/6i – potential upfront of $50m+5
dave444
13/11/2019
14:21
Following narratives told by others is what leads a person to the middle of a jungle with no swiss army knife. Look at the information yourself and decide for yourself what story it tells.
asat91
13/11/2019
12:52
That is not the narrative of the presentation
dave444
13/11/2019
12:51
Ah thanks Dave good job. It does say 'SFX-01 as second-line therapy to CDK4/6i – potential upfront of $50m' at the bottom of the breast cancer section. The asterix says the source is a pharma deals review in 2016, so that $50mill is an estimate based on the value of other upfront payments that have taken place in the past with other companies. It's not because they have a company lined up ready to pay it now. I would guess that's the estimated upfront payment for after a successful phase III trial.
asat91
13/11/2019
12:07
There was also a valuation in the finncap note of April 2 available on their website if you register. SAH was valued at around half
peterm10
13/11/2019
11:58
Go to EVG website click on investors then on shareholder information and open the link latest investor presentation
dave444
13/11/2019
11:39
Can you provide a link? The only presentation on the website close to April is the one below. It does not mention anything about partnering or a specific figure for breast cancer indication. hTTp://evgen.com/wp-content/uploads/2019/04/STEM-Headline-Results-Webcast-25Mar19-FINAL.pdf
asat91
13/11/2019
11:09
Evgen website April presentation on the slides for breast cancer Separate slides for SAH had different figures but these are obviously now worthless They were looking for partners from April so I would hope positive news soon
dave444
13/11/2019
10:26
Ah ok please do link me to where you found that information, I can't find it anywhere
asat91
13/11/2019
05:33
No it was specifically for Breast cancer but you would know that if you were an investor
dave444
12/11/2019
22:13
I think that 50 mill was for if SAH was successful. LWHL last post was reply to dave not you
asat91
12/11/2019
21:04
No they are partnering with anyone of knowledge would know - look at the presentations that you have consistently ignored!Very clear!More like receive $50m upfront
dave444
12/11/2019
21:00
My comment was obviously for Dave.
lovewinshatelosses
12/11/2019
20:58
They do need money; every company needs money. Funded until 2021 means they will be looking for more money in 2020 that's not disputable it's how the game is played.
asat91
12/11/2019
20:57
I promise I am neither in a panic nor looking to manipulate - look at my previous posts here - I too expect a bounce from these levels - and if significant shareholders are indeed topping up right now, I will be delighted and that would be terrific news for those of us who have held tight during this news - of which I am one.
lovewinshatelosses
12/11/2019
20:57
They do not need the money as they have already stated!Plus wealthy shareholders are already adding!
dave444
Chat Pages: 74  73  72  71  70  69  68  67  66  65  64  63  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191118 06:03:16